Please assess the completion status of the following clinical trial:

Trial Title: Immunogenicity Study of Antibody Persistence and Booster Effect of PENTAXIM™ at 18 Months in Healthy Argentinean Infants

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Toddler at 18 months of age (range: 510 days to 578 days of age inclusive)~* Participated in study A3L02 (NCT00831311) and has completed the three-dose primary series with either diphtheria, tetanus, pertussis (2-component acellular), recombinant Hepatitis B Hansenula and poliomyelitis vaccine adsorbed, and Haemophilus influenzae type b vaccine, conjugated to tetanus protein (DTaP-IPV-HB-PRP\~T) or PENTAXIM™ and ENGERIX B® PEDIATRICO at 2, 4, and 6 months of age~* Written informed consent form signed by at least one parent or by a legal representative and an independent witness~* Able to attend all scheduled visits and to comply with all trial procedures.~Exclusion Criteria:~* Participation in another clinical trial in the four weeks preceding the trial vaccination~* Planned participation in another clinical trial during the present trial period~* Congenital or acquired immunodeficiency, immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy within the preceding 6 months or long-term systemic corticosteroids therapy~* Systemic hypersensitivity to any of the vaccine components or history of a life-threatening reaction to a vaccine containing the same substances~* Chronic illness at a stage that could interfere with trial conduct or completion~* Blood or blood-derived products received in the last six months~* Any vaccination in the four weeks preceding the trial~* Vaccination with a vaccine containing diphtheria, tetanus, pertussis, Haemophilus influenzae type b, polio, or hepatitis B antigen, since the end of the primary series~* History of documented diphtheria, tetanus, pertussis, Haemophilus influenzae type b, polio, or hepatitis B infection(s) (confirmed either clinically, serologically, or microbiologically)~* Thrombocytopenia or bleeding disorder contraindicating intramuscular vaccination~* History of seizures~* Fever (axillary temperature ≥37.4°C or equivalent rectal temperature ≥38.0°C) or acute illness on the day of inclusion~* Known contraindication to further vaccination with a pertussis vaccine such as:~* Encephalopathy; Inconsolable crying for \>3 hours within 48 hours following vaccine injection~* Hypotonic hyporesponsive episode within 48 hours following vaccine injection~* Seizures with or without fever within three days following vaccine injection~* Axillary temperature \>39.4°C or equivalent rectal temperature \> 40.0°C within 48 hours following vaccine injection.

- Gender: ALL
- Minimum Age: 510 Days
- Maximum Age: 578 Days
- Healthy Volunteers: t

Study Arms:
- DTacP IPV HepB PRP-T Combined Vaccine Group (Type: EXPERIMENTAL): Participant will receive a booster dose of PENTAXIM™ having received DTacP-IPV-HepB-PRP-T (primary series) in Study A3L02.
- PENTAXIM™ and ENGERIX B® Vaccine Group (Type: ACTIVE_COMPARATOR): Participant will receive a booster dose of PENTAXIM™ having received ENGERIX B® and PEDIATRICO in Study A3L02 (Primary series)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete